Opinion|Videos|October 7, 2024
Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC
Key Takeaways
- PD-1/PD-L1 pathways are pivotal in cancer immunotherapy, enabling tumor immune evasion by inactivating T-cells through receptor-ligand interactions.
- Investigational agents in BCG-naive and unresponsive settings include gene therapy and intravesical treatments, targeting enhanced immune activation.
Panelists discuss how the PD-1/PD-L1 pathway plays a crucial role in cancer immunotherapy, outlining its mechanisms of action and highlighting the agents currently being investigated for patients who are BCG-naive or unresponsive, including gene therapy and intravesical options.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the role of the PD-1/PD-L1 pathways in cancer immunotherapy?
- What are their mechanisms of action?
What agents are being investigated in the BCG-naive and unresponsive setting? Gene therapy, intravesical?
Advertisement
Related to this article
VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Virtuoso Surgical expects to initiate a focused US launch at leading urology centers in 2027.
Pasritamig is being evaluated with or without JNJ-9401 in the ongoing phase 3 KLK2-comPAS trial.
The combination of nogapendekin alfa inbakicept plus BCG demonstrated a statistically significant improvement in efficacy vs BCG alone.
These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
2
Pasritamig combination yields 73% PSA response rate in phase 1 mCRPC study
3
FAQ: ASTRO guideline on hypofractionated radiation therapy for localized prostate cancer
4
Q&A: Suzanne B. Merrill, MD, FACS, on perioperative therapy in MIBC
5